MarketCap
Facebook
X
TelegramProgenity, Inc. Betriebsaufwand 2011-2026 | PROG
Betriebsaufwand Jährlich Progenity, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 176 M | 184 M | 150 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 184 M | 150 M | 170 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Anavex Life Sciences Corp.
AVXL
|
51.4 M | $ 3.02 | 1.0 % | $ 258 M |  USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
512 M | $ 90.9 | -0.31 % | $ 27.2 B | Germany |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.34 | 5.72 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Codexis
CDXS
|
31.5 M | $ 1.93 | 6.04 % | $ 168 M | USA |
 |
Cerus Corporation
CERS
|
149 M | $ 1.9 | 1.88 % | $ 362 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Cullinan Management
CGEM
|
242 M | $ 15.2 | 5.34 % | $ 916 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.69 | -2.31 % | $ 198 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
8.73 M | $ 0.46 | -13.46 % | $ 5.27 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.11 | -0.48 % | $ 439 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
16 M | $ 2.27 | 0.39 % | $ 1.01 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
206 M | $ 24.91 | 0.89 % | $ 3.05 B | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 8.3 | 3.36 % | $ 227 M | Israel |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
85.3 M | $ 10.37 | 1.97 % | $ 138 M | USA |
 |
Cardiff Oncology
CRDF
|
49.6 M | $ 1.6 | 0.95 % | $ 107 M | USA |
 |
Curis
CRIS
|
33.9 M | $ 0.53 | -3.64 % | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
173 M | $ 38.09 | 2.31 % | $ 3.58 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
668 M | $ 49.43 | -0.17 % | $ 4.44 B |  Schweiz |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
CytomX Therapeutics
CTMX
|
98.6 M | $ 4.41 | -3.4 % | $ 608 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
42 M | $ 0.87 | 1.26 % | $ 5.85 M | USA |
 |
Cue Biopharma
CUE
|
54 M | $ 0.17 | -7.12 % | $ 16.1 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 31.43 | 1.18 % | $ 2.09 B | USA |
 |
Cyclerion Therapeutics
CYCN
|
5.63 M | $ 4.34 | -29.51 % | $ 10.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | USA |